Ensemble Therapeutics, Boehringer Ingelheim deal

Ensemble partnered with Boehringer to use Ensemble's Ensemblin technology to discover macrocyclic drug candidates against undisclosed targets chosen by Boehringer. Ensemble will receive undisclosed upfront payments and research funding. The biotech also is eligible for up $186 million in milestones, plus royalties. Boehringer will have exclusive rights to develop and commercialize resulting candidates. ...